The city of New York, New York, currently has 25 active clinical trials seeking participants for COVID19 research studies.
RECOVER-SLEEP: Platform Protocol
Recruiting
The platform protocol is designed to be flexible so that it is suitable for a range of study settings and intervention types. Therefore, the platform protocol provides a general protocol structure that can be shared by multiple interventions and allows comparative analysis across the interventions. For example, objectives, measures, and endpoints are generalized in the platform protocol, but intervention-specific features are detailed in separate appendices. This platform protocol is a prospect... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/18/2025
Locations: Icahn School of Medicine at Mount Sinai, New York, New York
Conditions: Long COVID, Long COVID-19, Hypersomnia, Sleep Disturbance
tVNS in Long COVID-19
Recruiting
A prior open label study has shown that transcutaneous vagus nerve stimulation \[tVNS\] can improve the health of some patients with postacute sequelae of SARS-CoV-2 infection (PASC), severely affected enough to also fulfill criteria for myalgic encephalomyelitis / chronic fatigue syndrome (ME/CFS). The purpose of this study is to compare two sets of stimulus parameters to determine the one that best improves the health-related quality of life of these patients over a period of 6-weeks. Patients... Read More
Gender:
ALL
Ages:
Between 21 years and 70 years
Trial Updated:
04/17/2025
Locations: Icahn School of Medicine at Mount Sinai, New York, New York
Conditions: Long COVID, Chronic Fatigue Syndrome
Outpatient Treatment With Anti-Coronavirus Immunoglobulin
Recruiting
The primary objective of the Outpatient Treatment with Anti-Coronavirus Immunoglobulin (OTAC) (INSIGHT 012) trial is to compare the safety and efficacy of a single infusion of anti-COVID-19 hyperimmune intravenous immunoglobulin (hIVIG) versus placebo among adults with recently diagnosed severe acute respiratory syndrome - coronavirus 2 (SARS-CoV2) infection who do not require hospitalization. The primary endpoint of this double-blind randomized trial is a five-category ordinal outcome that asse... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/10/2025
Locations: Mount Sinai Beth Israel Hospital, New York, New York +1 locations
Conditions: COVID, SARS-CoV2 Infection, Covid19
Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE): Shionogi Protease Inhibitor (Ensitrelvir)
Recruiting
Treatments are needed to improve outcomes among patients hospitalized for COVID-19, including direct-acting antiviral (DAA) agents to mitigate the pathology driven by ongoing viral replication. This trial will evaluate S-217622 (ensitrelvir), an anti-SARS-CoV2 3C-like protease inhibitor (PI) developed by Shionogi \&; Co. Ltd. The study design is a randomized, placebo-controlled, multi-center international clinical trial that will evaluate the clinical efficacy of ensitrelvir when given in addit... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/02/2025
Locations: New York University Tisch Hospital (Site 301-013), New York, New York +3 locations
Conditions: COVID-19
ARMOR Study: COVID-19 Seroprevalence Among Healthcare Workers
Recruiting
The novel coronavirus (SARS-CoV-2) has spread all around the world and testing has posed a challenge globally. Health care providers are highly exposed and are an important group to test. On top of these concerns, health care workers are also stressed by the needs on responders in the COVID-19 crisis. The investigators will look at different ways to measure how common COVID-19 is among health care workers, how common is the presence of antibodies by serological tests (also known as serostatus).... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/02/2025
Locations: NewYork-Presbyterian Hosptial/Columbia University Irving Medical Center, New York, New York
Conditions: Covid-19, Coronavirus Infection, Coronavirus
CZI Rare As One: Co-designing an App and Wearable Based Compass for Rare Diseases
Recruiting
The CZI Rare As One study is a Chan Zuckerberg Initiative funded study that aims to co-design and pilot test unique symptom tracking and transmitting apps across 5 different sub-arms that includes individuals with Long COVID, Pancreatitis, Sarcoidosis, Vasolin-Containing Protein (VCP) disease and Primary Ciliary disease (PCD). This study aims to use multimodal digital health tools to enable patients to self-monitor their symptoms in passive and active ways.
Gender:
ALL
Ages:
14 years and above
Trial Updated:
04/01/2025
Locations: 4YouandMe, New York, New York
Conditions: Pancreatitis, Chronic, Sarcoidosis, VCP Disease, Long COVID, PCD, Symptoms and Signs, Wearables
RECOVER-AUTONOMIC Platform Protocol
Recruiting
This study is a platform protocol designed to be flexible so that it is suitable for a wide range of settings within health care systems and in community settings where it can be integrated into COVID-19 programs and subsequent treatment plans. This protocol is a prospective, multi-center, multi-arm, randomized, controlled platform trial evaluating various interventions for use in the treatment of autonomic dysfunction symptoms, including cardiovascular complications and postural orthostatic ta... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/24/2025
Locations: Columbia University Irving Medical Center - Appendix A & B, New York, New York
Conditions: Long COVID, Long Covid19, Long Covid-19
Strategies and Treatments for Respiratory Infections &Amp; Viral Emergencies (STRIVE): Immune Modulation Strategy Trial
Recruiting
COVID-19 can trigger a dysregulated immune response, and previous studies have shown that immune modulation can improve outcomes in hospitalized patients. This trial is designed to determine whether intensification of immune modulation early in the course of the disease (while patients are on low flow oxygen) with abatacept (active arm) combined with standard of care (SOC) improves recovery as compared with placebo + SOC (placebo arm). For both groups, intensification of immunomodulation will be... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/07/2025
Locations: New York University Langone Health (301-013), New York, New York +3 locations
Conditions: COVID-19
Cardiac Magnetic Resonance Tissue Characterization in COVID-19 Survivors
Recruiting
The purpose of this study is to test if visualizing the heart with cardiac MRI/echo will be important in the understanding cardiac function and prediction of cardiopulmonary symptoms, physical effort tolerance, and outcomes in COVID-19 survivors. If successful, the research will allow us to identify the causes of lasting cardiopulmonary symptoms and begin developing cardiac and lung directed therapies accordingly.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/21/2025
Locations: New York Presbyterian Queens, New York, New York +1 locations
Conditions: COVID-19 Pneumonia, COVID-19, COVID-19 Respiratory Infection, COVID-19 Acute Respiratory Distress Syndrome, COVID-19 Lower Respiratory Infection, COVID-19 Acute Bronchitis, Coronavirus Disease 2019
Synbiotic Therapy for NP-PASC
Recruiting
Gut microbiome dysbiosis has been noted in patients with Post-acute sequelae (PASC) of Severe Acute Respiratory Syndrome-CoronaVirus -2 (SARS-CoV-2). A study performed at Columbia found that plasma levels of the short chain fatty acid (SCFA), butyric acid, remained lower in people with Neuropsychiatric PASC (NP-PASC) than in people with PASC after SAR-CoV-2 infection. Synbiotics improve SCFA levels and are well-tolerated in the general population but have not been studied among people with PASC... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/14/2025
Locations: Columbia University Irving Medical Center, New York, New York
Conditions: Post-Acute COVID-19 Syndrome, Long COVID-19
Determinants of SARS (Severe Acute Respiratory Syndrome)-COV2 (COVID-19) Persistence After Convalescence
Recruiting
The 2019-2020 COVID-19 pandemic is the largest outbreak in recent history. It is not known how long after someone gets sick with COVID-19 and recovers that they can still infect other people. It is also not known how quickly people make antibodies against the virus, which help clear infection from the body. The investigators will enroll 300 people who had COVID-19 based on lab testing or confirmed exposure to participate. An additional 25 participants who have never tested positive for COVID and... Read More
Gender:
ALL
Ages:
7 years and above
Trial Updated:
01/03/2025
Locations: Columbia University Medical Center, New York, New York
Conditions: COVID-19, Corona Virus Infection, SARS-CoV 2
Humanity Neurotech Device Clinical Trial in Adults with Long COVID Cognitive Dysfunction
Recruiting
The purpose of this study is to assess the feasibility of an at-home MMT treatment in patients with cognitive dysfunction related to PASC, and to collect data on safety and efficacy to inform the design of larger clinical studies. A prospective randomized controlled study of 30 participants with PASC and moderate to severe cognitive dysfunction. Total study duration will be 8 weeks, including 4 weeks of treatment and 4 weeks of untreated follow up.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/17/2024
Locations: The Cohen Center for Recovery from Complex Chronic Illnesses (CoRE), New York, New York
Conditions: Post-Acute COVID-19 Syndrome, Cognitive Dysfunction